Table 3

Cumulative probabilities of discontinuing all antirheumatic and antiuveitis treatment because of inactive disease within 1, 2, 3, 4 and 5 years after diagnosis

Probability of discontinuing treatment and (number of subjects still in the cohort receiving continuous treatment)
ILAR categoryNumber*Within 1 yearWithin 2 yearsWithin 3 yearsWithin 4 yearsWithin 5 years
Whole cohort10840.098 (908)0.355 (490)0.460 (276)0.568 (137)0.672 (54)
Systemic arthritis720.085 (62)0.364 (38)0.398 (25)0.539 (13)0.613 (6)
Oligoarthritis4100.155 (318)0.463 (156)0.598 (76)0.735 (29)0.807 (9)
RF-negative Polyarthritis,2320.050 (208)0.207 (132)0.273 (90)0.401 (53)0.549 (22)
RF-positive Polyarthritis,440.023 (40)0.078 (26)0.078 (15)0.078 (8)0.078 (4)
Psoriatic arthritis640.145 (52)0.440 (21)0.561 (12)0.597 (9)0.739 (2)
Enthesitis-related arthritis1540.035 (136)0.318 (64)0.485 (33)0.606 (12)0.712 (5)
Undifferentiated1080.088 (92)0.376 (53)0.471 (24)0.471 (13)0.587 (6)
  • *Number of patients who contributed data for this analysis.

  • ILAR, International League of Associations for Rheumatology.